Skip to Main Content

Good morning. Elizabeth Cooney here, tag-teaming with Ed Silverman on a busy day. Let’s get right to the news.

Biogen (BIIB) and its Japanese pharma partner Eisai said Thursday that they were halting two Phase 3 clinical trials of aducanumab, a drug that was designed to slow the worsening of Alzheimer’s by targeting brain-destroying protein fragments known as beta-amyloid, STAT reports. An independent interim analysis concluded that aducanumab was unlikely to benefit Alzheimer’s patients compared to placebo when the trials completed, Biogen and Eisai said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!